Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension.

Bordenave J, Tu L, Berrebeh N, Thuillet R, Cumont A, Le Vely B, Fadel E, Nadaud S, Savale L, Humbert M, Huertas A, Guignabert C.

Arterioscler Thromb Vasc Biol. 2020 Jan 23:ATVBAHA119313715. doi: 10.1161/ATVBAHA.119.313715. [Epub ahead of print]

PMID:
31969018
2.

Connexin 43 Is a Promising Target for Pulmonary Hypertension due To Hypoxemic Lung Disease.

Bouvard C, Genet N, Phan C, Rode B, Thuillet R, Tu L, Robillard P, Campagnac M, Soleti R, Dumas De La Roque E, Delcambre F, Cronier L, Parpaite T, Maurat E, Berger P, Savineau JP, Marthan R, Guignabert C, Freund-Michel V, Guibert C.

Eur Respir J. 2019 Dec 20. pii: 1900169. doi: 10.1183/13993003.00169-2019. [Epub ahead of print]

PMID:
31862763
3.

Neutralization of CXCL12 attenuates established pulmonary hypertension in rats.

Bordenave J, Thuillet R, Tu L, Phan C, Cumont A, Marsol C, Huertas A, Savale L, Hibert M, Galzi JL, Bonnet D, Humbert M, Frossard N, Guignabert C.

Cardiovasc Res. 2019 Jun 7. pii: cvz153. doi: 10.1093/cvr/cvz153. [Epub ahead of print]

PMID:
31173066
4.

Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension.

Tu L, Desroches-Castan A, Mallet C, Guyon L, Cumont A, Phan C, Robert F, Thuillet R, Bordenave J, Sekine A, Huertas A, Ritvos O, Savale L, Feige JJ, Humbert M, Bailly S, Guignabert C.

Circ Res. 2019 Mar 15;124(6):846-855. doi: 10.1161/CIRCRESAHA.118.313356.

PMID:
30636542
5.

Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis.

Günther S, Bordenave J, Hua-Huy T, Nicco C, Cumont A, Thuillet R, Tu L, Quatremarre T, Guilbert T, Jalce G, Batteux F, Humbert M, Savale L, Guignabert C, Dinh-Xuan AT.

Int J Mol Sci. 2018 Dec 18;19(12). pii: E4105. doi: 10.3390/ijms19124105.

6.

Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension.

Poble PB, Phan C, Quatremare T, Bordenave J, Thuillet R, Cumont A, Huertas A, Tu L, Dorfmüller P, Humbert M, Ghigna MR, Savale L, Guignabert C.

FASEB J. 2019 Mar;33(3):3670-3679. doi: 10.1096/fj.201801659R. Epub 2018 Nov 27.

PMID:
30481487
7.

Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.

Rol N, de Raaf MA, Sun XQ, Kuiper VP, da Silva Gonçalves Bos D, Happé C, Kurakula K, Dickhoff C, Thuillet R, Tu L, Guignabert C, Schalij I, Lodder K, Pan X, Herrmann FE, van Nieuw Amerongen GP, Koolwijk P, Vonk-Noordegraaf A, de Man FS, Wollin L, Goumans MJ, Szulcek R, Bogaard HJ.

Cardiovasc Res. 2019 Feb 1;115(2):432-439. doi: 10.1093/cvr/cvy186.

PMID:
30032282
8.

Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.

Tamura Y, Phan C, Tu L, Le Hiress M, Thuillet R, Jutant EM, Fadel E, Savale L, Huertas A, Humbert M, Guignabert C.

J Clin Invest. 2018 May 1;128(5):1956-1970. doi: 10.1172/JCI96462. Epub 2018 Apr 9.

9.

Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension.

Le Hiress M, Akagah B, Bernadat G, Tu L, Thuillet R, Huertas A, Phan C, Fadel E, Simonneau G, Humbert M, Jalce G, Guignabert C.

J Med Chem. 2018 Apr 12;61(7):2725-2736. doi: 10.1021/acs.jmedchem.7b01312. Epub 2018 Mar 19.

PMID:
29526099
10.

Dasatinib increases endothelial permeability leading to pleural effusion.

Phan C, Jutant EM, Tu L, Thuillet R, Seferian A, Montani D, Huertas A, Bezu JV, Breijer F, Vonk Noordegraaf A, Humbert M, Aman J, Guignabert C.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701096. doi: 10.1183/13993003.01096-2017. Print 2018 Jan.

11.

A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population.

Kimura M, Tamura Y, Guignabert C, Takei M, Kosaki K, Tanabe N, Tatsumi K, Saji T, Satoh T, Kataoka M, Kamitsuji S, Kamatani N, Thuillet R, Tu L, Humbert M, Fukuda K, Sano M.

Oncotarget. 2017 Aug 24;8(43):74917-74926. doi: 10.18632/oncotarget.20459. eCollection 2017 Sep 26.

12.

Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension.

da Silva Gonçalves Bos D, Happé C, Schalij I, Pijacka W, Paton JFR, Guignabert C, Tu L, Thuillet R, Bogaard HJ, van Rossum AC, Vonk-Noordegraaf A, de Man FS, Handoko ML.

JACC Basic Transl Sci. 2017 Feb 1;2(1):22-35. doi: 10.1016/j.jacbts.2016.09.007. eCollection 2017 Feb.

13.

[Towards new targets for the treatment of pulmonary arterial hypertension : Importance of cell-cell communications].

Tu L, Ghigna MR, Phan C, Bordenave J, Le Hiress M, Thuillet R, Ricard N, Huertas A, Humbert M, Guignabert C.

Biol Aujourdhui. 2016;210(2):65-78. doi: 10.1051/jbio/2016010. Epub 2016 Sep 30. Review. French.

PMID:
27687598
14.

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Manéglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M.

J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249. Epub 2016 Aug 2.

15.

Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension.

Huertas A, Phan C, Bordenave J, Tu L, Thuillet R, Le Hiress M, Avouac J, Tamura Y, Allanore Y, Jovan R, Sitbon O, Guignabert C, Humbert M.

Chest. 2016 Jun;149(6):1482-93. doi: 10.1016/j.chest.2016.01.004. Epub 2016 Jan 21.

PMID:
26836928
16.

Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex.

Le Hiress M, Tu L, Ricard N, Phan C, Thuillet R, Fadel E, Dorfmüller P, Montani D, de Man F, Humbert M, Huertas A, Guignabert C.

Am J Respir Crit Care Med. 2015 Oct 15;192(8):983-97. doi: 10.1164/rccm.201402-0322OC.

PMID:
26203495
17.

Leptin signalling system as a target for pulmonary arterial hypertension therapy.

Huertas A, Tu L, Thuillet R, Le Hiress M, Phan C, Ricard N, Nadaud S, Fadel E, Humbert M, Guignabert C.

Eur Respir J. 2015 Apr;45(4):1066-80. doi: 10.1183/09031936.00193014. Epub 2015 Mar 5.

18.

Angiomatoid fibrous histiocytoma of the pulmonary artery: a multidisciplinary discussion.

Ghigna MR, Hamdi S, Petitpretz P, Rohnean A, Florea V, Mussot S, Dartevelle P, Dorfmuller P, Tu L, Thuillet R, Guignabert C, Thomas-de-Montpreville V.

Histopathology. 2014 Aug;65(2):278-82. doi: 10.1111/his.12429. Epub 2014 May 19.

PMID:
24702653
19.

Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.

Ricard N, Tu L, Le Hiress M, Huertas A, Phan C, Thuillet R, Sattler C, Fadel E, Seferian A, Montani D, Dorfmüller P, Humbert M, Guignabert C.

Circulation. 2014 Apr 15;129(15):1586-97. doi: 10.1161/CIRCULATIONAHA.113.007469. Epub 2014 Jan 30.

PMID:
24481949

Supplemental Content

Loading ...
Support Center